Triple-Negative Breast Cancer Treatment: From Initial Decisions to Emerging Options

Triple-Negative Breast Cancer Treatment: From Initial Decisions to Emerging Options Triple-negative breast cancer (TNBC) is negative for estrogen receptors (ER), progesterone receptors (PR), and HER2, so it does not have the hormone-receptor or HER2 targets used by several other breast cancer treatments. Triple-negative breast cancer treatment therefore relies more heavily on chemotherapy, immunotherapy, and other systemic approaches. Which combination is used, and in what sequence, depends on disease stage, tumor biology, biomarker results, and how the disease has responded to treatment so far. Why TNBC Treatment Looks Different Because TNBC does not express the receptors that hormone therapy or HER2-directed drugs target, chemotherapy has long formed the backbone of treatment across most disease stages. Over the past several years, immunotherapy and targeted approaches have added further options in specific circumstances. As a result, treatment for a given patient may combine systemic therapy, surgery, and sometimes radiation in different ways depending on the clinical setting. Key Factors Shaping TNBC Treatment Whether TNBC is localized, has recurred, or has spread to distant organs changes which treatments are appropriate, since each disease setting carries different goals and options. Beyond stage, several other factors are assessed: • • • • Pathology and receptor status confirmed on tumor tissue Germline BRCA1/2 testing, relevant to PARP inhibitor eligibility PD-L1 testing, which applies differently depending on the disease setting Response to any previous treatment and overall treatment tolerability These results guide the oncology team toward which treatments are appropriate for that specific disease setting. Treatment Timing and Response Around Surgery For many patients with higher-risk early-stage TNBC, systemic treatment is given before surgery as neoadjuvant therapy, allowing doctors to observe how the tumor responds while treatment is underway and, in some cases, shrinking the tumor ahead of the operation. Patients with smaller, node-negative tumors may instead undergo surgery first, with systemic treatment given afterward. For patients who do receive treatment before surgery, the sequence generally follows this path: Diagnosis & Staging → Neoadjuvant Treatment → Surgery → Pathology Review → Adjuvant Treatment Decision

The surgical specimen is then examined to determine whether a pathological complete response was achieved, meaning no residual invasive cancer is found in the breast or the sampled lymph nodes, or whether residual invasive disease remains. Residual disease after neoadjuvant treatment can prompt consideration of additional therapy, so surgery, systemic treatment, and pathology review work as one coordinated sequence. Established Treatments and Emerging TNBC Therapies Chemotherapy remains a major component of TNBC treatment across most settings. Immunotherapy is established for selected patients, such as certain high-risk early-stage disease treated before and after surgery, or metastatic disease meeting specific PD-L1 requirements. A germline BRCA1/2 pathogenic variant can make a PARP inhibitor an established option for selected patients. In metastatic TNBC, antibody-drug conjugates have also gained approval in specific settings, with eligibility depending on the individual agent, prior treatment, and biomarker status rather than one uniform rule. Investigational approaches are a separate category. Cancer vaccines, novel drug combinations, and biomarker-guided strategies are being studied for their potential to add to current treatment. Dendritic-cell therapies are also being investigated in TNBC, but they remain experimental and are not part of routine standard treatment. Readers looking for background on dendritic-cell immunotherapy and regional, interventional options used for metastatic disease can find it in this overview of TNBC treatment approaches in Germany. Category Current Role Status Chemotherapy Used across most disease settings, often alongside other treatment Established Immunotherapy (checkpoint inhibitors) Standard in specific early-stage and PDL1-selected metastatic settings Established for selected patients PARP inhibitors Option for selected patients with a germline BRCA1/2 pathogenic variant, depending on disease setting and treatment history Established for selected patients Antibody-drug conjugates Approved for specific metastatic TNBC settings, depending on the individual agent, prior treatment, and jurisdiction Established in specific settings Cancer vaccines, including dendriticcell approaches Studied for their ability to stimulate an anti-tumor immune response Investigational Treatment Decisions After Recurrence or Resistance When TNBC returns after initial treatment, or when a treatment that was working stops controlling the disease, the situation is reassessed before deciding on next steps. That reassessment typically includes: • Imaging to confirm the current extent of disease

• • A biopsy, when clinically appropriate Reassessing tumor biomarkers such as PD-L1, and reviewing prior germline BRCA1/2 results where relevant to treatment selection The original treatment is not automatically repeated; the next option depends on what was used before, how the disease responded, and current biomarker findings. A clinical trial can also be a reasonable avenue to discuss at this stage, offering access to approaches still being studied. Questions to Ask Your Doctor About TNBC Treatment A short list of questions can help clarify how your specific case is being approached. Depending on where you are in treatment, consider asking your oncologist or pathologist: • • What did my pathology report show about residual disease after treatment? • • • • Which newer TNBC treatments are already approved, and which are still being studied? How do my biomarker results, such as PD-L1 or BRCA1/2 status, affect which treatments apply to me? Is dendritic cell therapy considered standard care, or still investigational, for my situation? If my TNBC returns or stops responding to treatment, how would my plan change? Is a clinical trial a reasonable option to discuss at this point? Patients weighing these questions alongside their broader care can find general background on second-opinion and care-coordination resources for international patients through Treatment in Germany. Key Takeaway TNBC treatment is not determined by the subtype label alone. Bringing pathology, biomarker, and prior treatment information into every conversation with your care team is what determines which treatment options actually apply, whether the disease is newly diagnosed, in active treatment, or has returned.